Welcome to LookChem.com Sign In|Join Free

CAS

  • or

864868-03-1

3-(([2-(3,4-DIMETHOXYPHENYL)ETHYL]IMINO)METHYL)PHENOL is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

864868-03-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 864868-03-1 Structure

  • Basic information

    1. Product Name: 3-(([2-(3,4-DIMETHOXYPHENYL)ETHYL]IMINO)METHYL)PHENOL
    2. Synonyms: 3-(([2-(3,4-DIMETHOXYPHENYL)ETHYL]IMINO)METHYL)PHENOL
    3. CAS NO:864868-03-1
    4. Molecular Formula: C17H19NO3
    5. Molecular Weight: 285.34
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 864868-03-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 3-(([2-(3,4-DIMETHOXYPHENYL)ETHYL]IMINO)METHYL)PHENOL(CAS DataBase Reference)
    10. NIST Chemistry Reference: 3-(([2-(3,4-DIMETHOXYPHENYL)ETHYL]IMINO)METHYL)PHENOL(864868-03-1)
    11. EPA Substance Registry System: 3-(([2-(3,4-DIMETHOXYPHENYL)ETHYL]IMINO)METHYL)PHENOL(864868-03-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 864868-03-1(Hazardous Substances Data)

864868-03-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 864868-03-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,8,6 and 8 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 864868-03:
(8*8)+(7*6)+(6*4)+(5*8)+(4*6)+(3*8)+(2*0)+(1*3)=221
221 % 10 = 1
So 864868-03-1 is a valid CAS Registry Number.

864868-03-1Relevant articles and documents

Tetrahydroberberine derivative and application thereof

-

Paragraph 0287; 0288, (2016/10/08)

The invention relates to a tetrahydroberberine derivative and application thereof and relates to a compound represented by a formula (V) shown in the description, a preparation method therefor and application of the compound in medicine. Particularly, the invention relates to a derivative of the compound represented by the general formula (V), a preparation method for the derivative of the compound and use of the derivative of the compound in the prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type II diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the invention can also be used for lowering total cholesterol, LDL (Low-Density Lipoprotein)-cholesterol and triglyceride, improving liver LDL receptor expression and inhibiting PCSK9 expression.

Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor

Wang, Yan-Xiang,Wang, Yu-Ping,Zhang, Hao,Kong, Wei-Jia,Li, Ying-Hong,Liu, Fei,Gao, Rong-Mei,Liu, Ting,Jiang, Jian-Dong,Song, Dan-Qing

scheme or table, p. 6004 - 6008 (2010/06/16)

Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR). This one-drug-multiple-target characteristic might be suitable for the treatment of metabolic syndrome. In searching for up-regulators effective for both LDLR and InsR expression, the structure-activity relationship (SAR) analysis for BBR analogues was done. Fourteen BBR analogues were designed, synthesized and biologically evaluated. SAR analysis revealed that appropriate modifications on the phenyl ring A or D of BBR might retain the up-regulatory activities on the expression of both LDLR and InsR. Among these compounds, compound 13a bearing 9-methoxy and 10-hydroxyl on the ring D showed promising activities on either LDLR or InsR gene expression. The 10-hydroxyl of 13a could be an arm to connect proper chemical groups for optimizing drug-bioavailability in vivo. Thus, 13a could be considered to be a parent compound to make pro-drugs for either blood lipids or glucose.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 864868-03-1